JOP20200298A1 - مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها - Google Patents
مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بهاInfo
- Publication number
- JOP20200298A1 JOP20200298A1 JOP/2020/0298A JOP20200298A JOP20200298A1 JO P20200298 A1 JOP20200298 A1 JO P20200298A1 JO P20200298 A JOP20200298 A JO P20200298A JO P20200298 A1 JOP20200298 A1 JO P20200298A1
- Authority
- JO
- Jordan
- Prior art keywords
- vmat2 inhibitor
- compositions
- inhibitor compounds
- methods relating
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
غير متوفر
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862684935P | 2018-06-14 | 2018-06-14 | |
PCT/US2019/037046 WO2019241555A1 (en) | 2018-06-14 | 2019-06-13 | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20200298A1 true JOP20200298A1 (ar) | 2020-11-22 |
Family
ID=67263041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2020/0298A JOP20200298A1 (ar) | 2018-06-14 | 2019-06-13 | مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP3806856A1 (ar) |
JP (1) | JP2021528386A (ar) |
KR (1) | KR20210021006A (ar) |
CN (1) | CN112638387A (ar) |
AU (1) | AU2019287524A1 (ar) |
BR (1) | BR112020024018A2 (ar) |
CA (1) | CA3100694A1 (ar) |
EA (1) | EA202092750A1 (ar) |
IL (1) | IL278758A (ar) |
JO (1) | JOP20200298A1 (ar) |
MA (1) | MA52896A (ar) |
MX (1) | MX2020013004A (ar) |
PH (1) | PH12020552088A1 (ar) |
SG (1) | SG11202011544UA (ar) |
TW (1) | TW202011963A (ar) |
WO (1) | WO2019241555A1 (ar) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3002074A1 (en) | 2015-10-30 | 2017-05-04 | Neurocrine Biosciences, Inc. | Valbenazine salts and polymorphs thereof |
JP6869988B2 (ja) | 2015-12-23 | 2021-05-12 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | (S)−(2R,3R,11bR)−3−イソブチル−9,10−ジメトキシ−2,3,4,6,7,11b−ヘキサヒドロ−1H−ピリド[2,1−a]イソキノリン−2−イル2−アミノ−3−メチルブタノエートジ(4−メチルベンゼンスルホネート)の調製のための合成方法 |
CN110769826A (zh) | 2017-01-27 | 2020-02-07 | 纽罗克里生物科学有限公司 | 施用某些vmat2抑制剂的方法 |
EP3684333A2 (en) | 2017-09-21 | 2020-07-29 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
BR112021000019A2 (pt) | 2018-08-15 | 2021-04-06 | Neurocrine Biosciences Inc. | Métodos para administração de certos inibidores de vmat2 |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
WO2023076568A1 (en) * | 2021-10-29 | 2023-05-04 | Neurocrine Biosciences, Inc. | Valbenazine compositions |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
HU196714B (en) | 1984-10-04 | 1989-01-30 | Monsanto Co | Process for producing non-aqueous composition comprising somatotropin |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
ATE268591T1 (de) | 1995-06-27 | 2004-06-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
NZ334914A (en) | 1996-10-01 | 2000-09-29 | Stanford Res Inst Int | Taste-masked microcapsule compositions and methods of manufacture using a phase seperation-coacervation technique |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
AU7871298A (en) | 1996-12-20 | 1998-07-17 | Takeda Chemical Industries Ltd. | Method of producing a sustained-release preparation |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
CA2420535A1 (en) | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
CA2771539A1 (en) | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
US8782398B2 (en) | 2012-06-26 | 2014-07-15 | Intel Corporation | Secure user presence detection and authentication |
JP6362601B2 (ja) | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドAuspex Pharmaceuticals, Inc. | 小胞モノアミン輸送体2の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
CA2938581C (en) | 2014-02-07 | 2023-02-28 | Neurocrine Biosciences, Inc. | Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof |
KR20200133003A (ko) | 2014-05-06 | 2020-11-25 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 과다운동성 운동 장애의 치료를 위한 vmat2 억제제 |
JP6755254B2 (ja) * | 2015-02-06 | 2020-09-16 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | [9,10−ジメトキシ−3−(2−メチルプロピル)−1H,2H,3H,4H,6H,7H,11bH−ピリド[2,1−a]イソキノリン−2−イル]メタノール、ならびにそれに関する化合物、組成物、および方法 |
CN113713108A (zh) | 2015-06-23 | 2021-11-30 | 纽罗克里生物科学有限公司 | 用于治疗神经学疾病或病症的vmat2抑制剂 |
TW202345829A (zh) | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪(valbenazine)於治療精神分裂症或情感性精神分裂症之用途 |
RU2771164C2 (ru) | 2017-04-01 | 2022-04-27 | Адептио Фармасьютикалз Лимитед | (+)-альфа-дигидротетрабеназин для использования при лечении двигательного расстройства |
JP7250692B2 (ja) | 2017-04-01 | 2023-04-03 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療における使用のためのジヒドロテトラベナジン |
JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
EP3684333A2 (en) | 2017-09-21 | 2020-07-29 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
-
2019
- 2019-06-13 EP EP19739758.1A patent/EP3806856A1/en active Pending
- 2019-06-13 MA MA052896A patent/MA52896A/fr unknown
- 2019-06-13 KR KR1020217000734A patent/KR20210021006A/ko unknown
- 2019-06-13 EA EA202092750A patent/EA202092750A1/ru unknown
- 2019-06-13 WO PCT/US2019/037046 patent/WO2019241555A1/en active Application Filing
- 2019-06-13 SG SG11202011544UA patent/SG11202011544UA/en unknown
- 2019-06-13 CN CN201980039832.5A patent/CN112638387A/zh active Pending
- 2019-06-13 JP JP2020568772A patent/JP2021528386A/ja active Pending
- 2019-06-13 JO JOP/2020/0298A patent/JOP20200298A1/ar unknown
- 2019-06-13 AU AU2019287524A patent/AU2019287524A1/en active Pending
- 2019-06-13 MX MX2020013004A patent/MX2020013004A/es unknown
- 2019-06-13 CA CA3100694A patent/CA3100694A1/en active Pending
- 2019-06-13 TW TW108120550A patent/TW202011963A/zh unknown
- 2019-06-13 BR BR112020024018-4A patent/BR112020024018A2/pt unknown
-
2020
- 2020-11-17 IL IL278758A patent/IL278758A/en unknown
- 2020-12-04 PH PH12020552088A patent/PH12020552088A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3100694A1 (en) | 2019-12-19 |
WO2019241555A1 (en) | 2019-12-19 |
BR112020024018A2 (pt) | 2021-02-23 |
EA202092750A1 (ru) | 2021-05-13 |
EP3806856A1 (en) | 2021-04-21 |
CN112638387A (zh) | 2021-04-09 |
IL278758A (en) | 2021-01-31 |
MX2020013004A (es) | 2021-02-17 |
AU2019287524A1 (en) | 2020-12-24 |
TW202011963A (zh) | 2020-04-01 |
JP2021528386A (ja) | 2021-10-21 |
SG11202011544UA (en) | 2020-12-30 |
MA52896A (fr) | 2021-04-21 |
KR20210021006A (ko) | 2021-02-24 |
PH12020552088A1 (en) | 2021-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020552088A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
AR126205A2 (es) | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario | |
EA201792092A1 (ru) | Редактирование генов с использованием tat-индуцируемой crispr-эндонуклеазы | |
MY190855A (en) | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof | |
CR20210235A (es) | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp | |
MX2022001061A (es) | Agentes de interleuquina-2 y usos de los mismos. | |
CR20200228A (es) | COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554) | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
MX2017006464A (es) | Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton. | |
MX2017015225A (es) | Inhibidores de la autotaxina y sus usos. | |
EA202190708A1 (ru) | Модуляторы экспрессии pnpla3 | |
GEP20186876B (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
MX2021015992A (es) | Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico. | |
PH12020551573A1 (en) | Pharmaceutical compositions for inhibiting inflammatory cytokines | |
MX2021001612A (es) | Compuestos utiles en terapia del vih. | |
MX2021006463A (es) | Metodos para el tratamiento de trastornos de expansion repetida de trinucleotidos asociados con actividad msh3. | |
MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
MX2021012634A (es) | Neurogénesis. | |
MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
ZA201907101B (en) | Methods of preventing or treating ophthalmic diseases | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
MY191993A (en) | Use of isolated fractions of mastic gum for treating optic neuropathy | |
MX2016008968A (es) | Compuestos organicos. |